Hamlet BioPharma AB Logo

Hamlet BioPharma AB

Developing selective therapies for cancer and infections like bladder cancer and UTIs.

HAMLET | SPGR

Overview

Corporate Details

ISIN(s):
SE0015661145 (+2 more)
LEI:
549300HJV2LJY4CDBR64
Country:
Sweden
Address:
Klinikgatan 32, 222 42 LUND
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Hamlet BioPharma AB is a clinical-stage pharmaceutical company developing novel therapies for cancer and infections. Its lead oncology candidate, Alpha1H, is a tumor-killing protein-lipid complex designed to selectively target and eliminate tumor cells while sparing healthy tissue. Alpha1H has successfully completed Phase II trials for bladder cancer, demonstrating significant tumor reduction and immune system activation. The company is also advancing immunotherapy as an alternative to antibiotics. Its IL-1 inhibitor, anakinra, has completed Phase II studies showing positive results in treating patients with recurrent urinary tract infections and Bladder Pain Syndrome (interstitial cystitis). Hamlet BioPharma's pipeline focuses on creating highly specific treatments with improved safety profiles for significant unmet medical needs.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Hamlet BioPharma AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Hamlet BioPharma AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Hamlet BioPharma AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Sweden
MBOLIC
Milton Essex Spolka Akcyjna Logo
Develops AI-powered, non-invasive systems for allergy diagnostics & personalized medicine.
Poland
MTN
Molecular Partners AG Logo
Pioneering DARPin protein drugs for complex diseases in oncology and virology.
Switzerland
MOLN
MorphoSys AG Logo
Biopharma company creating antibody therapies for oncology, with a focus on blood cancers.
Germany
MOR
N4 PHARMA PLC Logo
Developing a nanoparticle delivery system for advanced gene and vaccine therapies.
United Kingdom
N4P
NextGen Biomed Ltd. Logo
R&D of biotech medical devices for diabetes care and topical skin treatments.
Israel
NXGN
Nicox S.A. Logo
Developing innovative ophthalmology drugs for glaucoma and ocular hypertension.
France
COX
ONCIMMUNE HOLDINGS PLC Logo
Antibody biomarker discovery platform for pharma and biotech partners in oncology and autoimmune disease.
United Kingdom
ONC
OncoZenge AB Logo
Developing a non-opioid lozenge for oral pain relief in cancer patients.
Sweden
ONCOZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.